NCT07002112 is a Phase 1 clinical trial of LVIVO-TaVec100 product in Relapsed/Refractory B-cell Malignancies, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT07002112?

NCT07002112 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT07002112?

Interventions in NCT07002112: LVIVO-TaVec100 product.

What condition does NCT07002112 study?

NCT07002112 studies Relapsed/Refractory B-cell Malignancies.

Is NCT07002112 still recruiting?

NCT07002112 is currently recruiting now. Last updated 12 August 2025.

Last reviewed 2025-08-12 · How we verify

NCT07002112

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Recruiting now Phase 1 Last updated 12 August 2025

What this trial tests

Phase 1 trial testing LVIVO-TaVec100 product in Relapsed/Refractory B-cell Malignancies in 30 participants. Currently enrolling.

Timeline

23 May 2025

Primary endpoint
30 June 2027

30 June 2029

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	23 May 2025
Primary completion	30 June 2027
Estimated completion	30 June 2029
Sites	6 locations across China

Drugs / interventions tested

LVIVO-TaVec100 product — full drug profile →

Conditions studied

Relapsed/Refractory B-cell Malignancies — all drugs for Relapsed/Refractory B-cell Malignancies →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 65, any sex, with Relapsed/Refractory B-cell Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec100 product in the Treatment of Relapsed/Refractory B-cell Malignancies.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

In vivo CAR cell therapy: from bench to bedside.
Xu J, Chen Z, Su L, Ren A, et al · · 2025 · cited 7× · PMID 41261423 · DOI 10.1186/s13045-025-01759-2
Revolution in Cell Therapy: In Vivo Chimeric-Antigen-Receptor-T-Cell Therapy Breakthroughs and Promises for the Future.
Lai M, Shao W, Mao J, Ye Q. · · 2025 · cited 2× · PMID 41079670 · DOI 10.34133/research.0917
Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms.
He L, Sun Y, Ma B, Lang G, et al · · 2026 · PMID 42093990 · DOI 10.3389/fimmu.2026.1772428
<i>In Vivo</i> CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation.
Hao L, Lu J, Xue J. · · 2026 · PMID 42065060 · DOI 10.32604/or.2026.076420
In vivo CAR-cell therapy: current challenges and emerging therapeutic advances.
Yang YM, Bao B, Cao YH, Yao J, et al · · 2026 · PMID 42008208 · DOI 10.1186/s43556-026-00447-y
In vivo engineering of CAR-T cells: delivery strategies and clinical translation.
Gao Y, Hu J, An N, Wen X, et al · · 2026 · PMID 41593732 · DOI 10.1186/s40364-026-00899-y

Verify or expand the search:

Other recruiting trials for Relapsed/Refractory B-cell Malignancies

Currently open trials in the same condition.

NCT07345728 — Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies · NA · recruiting
NCT07309900 — IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies · Phase 1 · recruiting
NCT07240974 — Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies · EARLY_PHASE1 · recruiting
NCT05780034 — A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies · Phase 1 · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07002112 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 12 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07002112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing